{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:06:30Z","timestamp":1789427190831,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76502-7","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:03:22Z","timestamp":1786806202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib\/II study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8814-4339","authenticated-orcid":false,"given":"Mo","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiancheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boqiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-9025","authenticated-orcid":false,"given":"Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-3190","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"76502_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"76502_CR2","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71, 264\u2013279 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"76502_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"76502_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"76502_CR5","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. Bmj 385, e078876 (2024).","journal-title":"Bmj"},{"key":"76502_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. Jama 330, 2064\u20132074 (2023).","journal-title":"Jama"},{"key":"76502_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","volume":"23","author":"T Yoshida","year":"2022","unstructured":"Yoshida, T. et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol. Ther. 23, 191\u2013200 (2022).","journal-title":"Cancer Biol. Ther."},{"key":"76502_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13000-021-01099-y","volume":"16","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Diagn. Pathol. 16, 38 (2021).","journal-title":"Diagn. Pathol."},{"key":"76502_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"76502_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31\u201339 (2014).","journal-title":"Lancet"},{"key":"76502_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448\u20131454 (2016).","journal-title":"J. Clin. Oncol."},{"key":"76502_CR12","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968\u20133976 (2011).","journal-title":"J. Clin. Oncol."},{"key":"76502_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s10120-014-0351-5","volume":"18","author":"L Shen","year":"2015","unstructured":"Shen, L. et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18, 168\u2013176 (2015).","journal-title":"Gastric Cancer"},{"key":"76502_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76502_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76502_CR16","doi-asserted-by":"publisher","unstructured":"Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aak9679 (2017).","DOI":"10.1126\/scitranslmed.aak9679"},{"key":"76502_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin. Cancer Res. 28, 793\u2013809 (2022).","journal-title":"Clin. Cancer Res."},{"key":"76502_CR18","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"76502_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76502_CR20","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76502_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5414\/CP203349","volume":"57","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects. Int. J. Clin. Pharm. Ther. 57, 167\u2013174 (2019).","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"76502_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.21037\/tlcr.2019.12.23","volume":"8","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Biosimilar candidate IBI305 plus paclitaxel\/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl. Lung Cancer Res. 8, 989\u2013999 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"76502_CR23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23, 1167\u20131179 (2022).","journal-title":"Lancet Oncol."},{"key":"76502_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"76502_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S1470-2045(23)00358-3","volume":"24","author":"SL Cytryn","year":"2023","unstructured":"Cytryn, S. L. et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 24, 1073\u20131082 (2023).","journal-title":"Lancet Oncol."},{"key":"76502_CR26","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","volume":"27","author":"Z Peng","year":"2021","unstructured":"Peng, Z. et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res 27, 3069\u20133078 (2021).","journal-title":"Clin. Cancer Res"},{"key":"76502_CR27","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1200\/JCO-25-00748","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study. J. Clin. Oncol. 43, 2502\u20132514 (2025).","journal-title":"J. Clin. Oncol."},{"key":"76502_CR28","doi-asserted-by":"crossref","unstructured":"Kuonqui, K. et al. Dysregulation of lymphatic endothelial VEGFR3 signaling in disease. Cells 13, 68 (2024).","DOI":"10.3390\/cells13010068"},{"key":"76502_CR29","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"76502_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ejso.2006.03.003","volume":"32","author":"Y Yonemura","year":"2006","unstructured":"Yonemura, Y., Bandou, E., Kawamura, T., Endou, Y. & Sasaki, T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur. J. Surg. Oncol. 32, 602\u2013606 (2006).","journal-title":"Eur. J. Surg. Oncol."},{"key":"76502_CR31","doi-asserted-by":"publisher","unstructured":"Ruiz Hisp\u00e1n, E., Pedregal, M., Cristobal, I., Garc\u00eda-Foncillas, J. & Caram\u00e9s, C. Immunotherapy for peritoneal metastases from gastric cancer: rationale, current practice and ongoing trials. J. Clin. Med. 10, https:\/\/doi.org\/10.3390\/jcm10204649 (2021).","DOI":"10.3390\/jcm10204649"},{"key":"76502_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 23, 283 (2023).","journal-title":"BMC Gastroenterol."},{"key":"76502_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0061-0","volume":"9","author":"MB Schaaf","year":"2018","unstructured":"Schaaf, M. B., Garg, A. D. & Agostinis, P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 9, 115 (2018).","journal-title":"Cell Death Dis."},{"key":"76502_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12272-022-01389-z","volume":"45","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J., Ji, Y. R. & Lee, Y. M. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch. Pharm. Res. 45, 401\u2013416 (2022).","journal-title":"Arch. Pharm. Res."},{"key":"76502_CR35","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/2767-9764.CRC-23-0496","volume":"4","author":"N Rustgi","year":"2024","unstructured":"Rustgi, N. et al. Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer. Cancer Res. Commun. 4, 1399\u20131409 (2024).","journal-title":"Cancer Res. Commun."},{"key":"76502_CR36","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR\/MSI-H gastrointestinal cancer. J. Immunother. Cancer 10, https:\/\/doi.org\/10.1136\/jitc-2022-004703 (2022).","DOI":"10.1136\/jitc-2022-004703"},{"key":"76502_CR37","doi-asserted-by":"publisher","first-page":"e15514","DOI":"10.1200\/JCO.2019.37.15_suppl.e15514","volume":"37","author":"X Yu","year":"2019","unstructured":"Yu, X. et al. Association of CDH1 mutation with prognosis in gastric adenocarcinoma. J. Clin. Oncol. 37, e15514\u2013e15514 (2019).","journal-title":"J. Clin. Oncol."},{"key":"76502_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","volume":"14","author":"CA Bradley","year":"2017","unstructured":"Bradley, C. A. et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 14, 562\u2013576 (2017).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:51:43Z","timestamp":1789426303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76502"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76502-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9824"}}